The evolution of primary chemotherapy in breast cancer treatment

Tadashi Ikeda, Hiromitsu Jinno, Masaki Kitajima

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Primary chemotherapy may be thought of as having evolved over three generations. First-generation primary chemotherapy followed trials which proved that the prognosis of breast cancer patients receiving primary chemotherapy was the same as that of patients receiving post-operative chemotherapy. Secondgeneration primary chemotherapy followed trials which demonstrated that regimens containing anthracyclines and taxanes yielded complete pathological response rates (pCR) of over 20%. Third-generation primary chemotherapy followed trials which demonstrated that inclusion of newer agents, such as trastuzumab and capetitabine, in combination with taxanes could yield pathological CR rates of over 30%. In third-generation primary chemotherapy, predictive factors, especially those analyzed by DNA array analysis, play a key role. Other issues, including the relevance of sentinel node biopsy after primary chemotherapy and the importance of marking the site of the primary tumor before primary chemotherapy in cases showing cCR, are highlighted. This article deals with the history of the evolution of primary chemotherapy, along with a discussion of some relevant issues.

Original languageEnglish
Pages (from-to)148-155
Number of pages8
JournalBreast Cancer
Volume11
Issue number2
DOIs
Publication statusPublished - 2004 Apr

Fingerprint

Breast Neoplasms
Drug Therapy
Therapeutics
Taxoids
Anthracyclines
Oligonucleotide Array Sequence Analysis
History
Biopsy
Neoplasms

Keywords

  • Breast Cancer
  • Neoadjuvant chemotherapy
  • Preoperative chemotherapy

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Pharmacology (medical)

Cite this

The evolution of primary chemotherapy in breast cancer treatment. / Ikeda, Tadashi; Jinno, Hiromitsu; Kitajima, Masaki.

In: Breast Cancer, Vol. 11, No. 2, 04.2004, p. 148-155.

Research output: Contribution to journalArticle

Ikeda, T, Jinno, H & Kitajima, M 2004, 'The evolution of primary chemotherapy in breast cancer treatment', Breast Cancer, vol. 11, no. 2, pp. 148-155. https://doi.org/10.1007/BF02968294
Ikeda, Tadashi ; Jinno, Hiromitsu ; Kitajima, Masaki. / The evolution of primary chemotherapy in breast cancer treatment. In: Breast Cancer. 2004 ; Vol. 11, No. 2. pp. 148-155.
@article{4d64c9471df14429ba054a7d0bb16a3d,
title = "The evolution of primary chemotherapy in breast cancer treatment",
abstract = "Primary chemotherapy may be thought of as having evolved over three generations. First-generation primary chemotherapy followed trials which proved that the prognosis of breast cancer patients receiving primary chemotherapy was the same as that of patients receiving post-operative chemotherapy. Secondgeneration primary chemotherapy followed trials which demonstrated that regimens containing anthracyclines and taxanes yielded complete pathological response rates (pCR) of over 20{\%}. Third-generation primary chemotherapy followed trials which demonstrated that inclusion of newer agents, such as trastuzumab and capetitabine, in combination with taxanes could yield pathological CR rates of over 30{\%}. In third-generation primary chemotherapy, predictive factors, especially those analyzed by DNA array analysis, play a key role. Other issues, including the relevance of sentinel node biopsy after primary chemotherapy and the importance of marking the site of the primary tumor before primary chemotherapy in cases showing cCR, are highlighted. This article deals with the history of the evolution of primary chemotherapy, along with a discussion of some relevant issues.",
keywords = "Breast Cancer, Neoadjuvant chemotherapy, Preoperative chemotherapy",
author = "Tadashi Ikeda and Hiromitsu Jinno and Masaki Kitajima",
year = "2004",
month = "4",
doi = "10.1007/BF02968294",
language = "English",
volume = "11",
pages = "148--155",
journal = "Breast Cancer",
issn = "1340-6868",
publisher = "Springer Japan",
number = "2",

}

TY - JOUR

T1 - The evolution of primary chemotherapy in breast cancer treatment

AU - Ikeda, Tadashi

AU - Jinno, Hiromitsu

AU - Kitajima, Masaki

PY - 2004/4

Y1 - 2004/4

N2 - Primary chemotherapy may be thought of as having evolved over three generations. First-generation primary chemotherapy followed trials which proved that the prognosis of breast cancer patients receiving primary chemotherapy was the same as that of patients receiving post-operative chemotherapy. Secondgeneration primary chemotherapy followed trials which demonstrated that regimens containing anthracyclines and taxanes yielded complete pathological response rates (pCR) of over 20%. Third-generation primary chemotherapy followed trials which demonstrated that inclusion of newer agents, such as trastuzumab and capetitabine, in combination with taxanes could yield pathological CR rates of over 30%. In third-generation primary chemotherapy, predictive factors, especially those analyzed by DNA array analysis, play a key role. Other issues, including the relevance of sentinel node biopsy after primary chemotherapy and the importance of marking the site of the primary tumor before primary chemotherapy in cases showing cCR, are highlighted. This article deals with the history of the evolution of primary chemotherapy, along with a discussion of some relevant issues.

AB - Primary chemotherapy may be thought of as having evolved over three generations. First-generation primary chemotherapy followed trials which proved that the prognosis of breast cancer patients receiving primary chemotherapy was the same as that of patients receiving post-operative chemotherapy. Secondgeneration primary chemotherapy followed trials which demonstrated that regimens containing anthracyclines and taxanes yielded complete pathological response rates (pCR) of over 20%. Third-generation primary chemotherapy followed trials which demonstrated that inclusion of newer agents, such as trastuzumab and capetitabine, in combination with taxanes could yield pathological CR rates of over 30%. In third-generation primary chemotherapy, predictive factors, especially those analyzed by DNA array analysis, play a key role. Other issues, including the relevance of sentinel node biopsy after primary chemotherapy and the importance of marking the site of the primary tumor before primary chemotherapy in cases showing cCR, are highlighted. This article deals with the history of the evolution of primary chemotherapy, along with a discussion of some relevant issues.

KW - Breast Cancer

KW - Neoadjuvant chemotherapy

KW - Preoperative chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=16544384743&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=16544384743&partnerID=8YFLogxK

U2 - 10.1007/BF02968294

DO - 10.1007/BF02968294

M3 - Article

VL - 11

SP - 148

EP - 155

JO - Breast Cancer

JF - Breast Cancer

SN - 1340-6868

IS - 2

ER -